190 related articles for article (PubMed ID: 32767939)
41. In vitro antitumor activities of the lichen compounds olivetoric, physodic and psoromic acid in rat neuron and glioblastoma cells.
Emsen B; Aslan A; Togar B; Turkez H
Pharm Biol; 2016 Sep; 54(9):1748-62. PubMed ID: 26704132
[TBL] [Abstract][Full Text] [Related]
42. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
43. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis.
Yang YP; Chang YL; Huang PI; Chiou GY; Tseng LM; Chiou SH; Chen MH; Chen MT; Shih YH; Chang CH; Hsu CC; Ma HI; Wang CT; Tsai LL; Yu CC; Chang CJ
J Cell Physiol; 2012 Mar; 227(3):976-93. PubMed ID: 21503893
[TBL] [Abstract][Full Text] [Related]
44. The Recent Research Progress of NF-κB Signaling on the Proliferation, Migration, Invasion, Immune Escape and Drug Resistance of Glioblastoma.
Shi P; Xu J; Cui H
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373484
[TBL] [Abstract][Full Text] [Related]
45. The Evaluation of Glioblastoma Cell Dissociation and Its Influence on Its Behavior.
Skarkova V; Krupova M; Vitovcova B; Skarka A; Kasparova P; Krupa P; Kralova V; Rudolf E
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540507
[TBL] [Abstract][Full Text] [Related]
46. The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review.
Mohtashami E; Shafaei-Bajestani N; Mollazadeh H; Mousavi SH; Jalili-Nik M; Sahebkar A; Afshari AR
Curr Drug Metab; 2020; 21(8):564-578. PubMed ID: 32664839
[TBL] [Abstract][Full Text] [Related]
47. Combined treatment of AT101 and demethoxycurcumin yields an enhanced anti-proliferative effect in human primary glioblastoma cells.
Mehner M; Kubelt C; Adamski V; Schmitt C; Synowitz M; Held-Feindt J
J Cancer Res Clin Oncol; 2020 Jan; 146(1):117-126. PubMed ID: 31844979
[TBL] [Abstract][Full Text] [Related]
48. EIF4A3-induced circular RNA MMP9 (circMMP9) acts as a sponge of miR-124 and promotes glioblastoma multiforme cell tumorigenesis.
Wang R; Zhang S; Chen X; Li N; Li J; Jia R; Pan Y; Liang H
Mol Cancer; 2018 Nov; 17(1):166. PubMed ID: 30470262
[TBL] [Abstract][Full Text] [Related]
49. Astrocytes, the rising stars of the glioblastoma microenvironment.
Brandao M; Simon T; Critchley G; Giamas G
Glia; 2019 May; 67(5):779-790. PubMed ID: 30240060
[TBL] [Abstract][Full Text] [Related]
50. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
[TBL] [Abstract][Full Text] [Related]
51. Antiangiogenic therapies in glioblastoma multiforme.
McNamara MG; Mason WP
Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
[TBL] [Abstract][Full Text] [Related]
52. An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective.
Pawlowska E; Szczepanska J; Szatkowska M; Blasiak J
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562589
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
Reardon DA; Wen PY
Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
Gao Y; Fotovati A; Lee C; Wang M; Cote G; Guns E; Toyota B; Faury D; Jabado N; Dunn SE
Mol Cancer Ther; 2009 Dec; 8(12):3276-84. PubMed ID: 19996271
[TBL] [Abstract][Full Text] [Related]
55. In silico analysis identified miRNA‑based therapeutic agents against glioblastoma multiforme.
Xiong DD; Xu WQ; He RQ; Dang YW; Chen G; Luo DZ
Oncol Rep; 2019 Apr; 41(4):2194-2208. PubMed ID: 30816530
[TBL] [Abstract][Full Text] [Related]
56. Cyclooxygenase-2 in glioblastoma multiforme.
Qiu J; Shi Z; Jiang J
Drug Discov Today; 2017 Jan; 22(1):148-156. PubMed ID: 27693715
[TBL] [Abstract][Full Text] [Related]
57. Isofuranodiene synergizes with temozolomide in inducing glioma cells death.
Brunetti A; Marinelli O; Morelli MB; Iannarelli R; Amantini C; Russotti D; Santoni G; Maggi F; Nabissi M
Phytomedicine; 2019 Jan; 52():51-59. PubMed ID: 30599912
[TBL] [Abstract][Full Text] [Related]
58. Prospective of curcumin, a pleiotropic signalling molecule from Curcuma longa in the treatment of Glioblastoma.
Luthra PM; Lal N
Eur J Med Chem; 2016 Feb; 109():23-35. PubMed ID: 26748069
[TBL] [Abstract][Full Text] [Related]
59. Autophagy, the Trojan horse to combat glioblastomas.
Lefranc F; Kiss R
Neurosurg Focus; 2006 Apr; 20(4):E7. PubMed ID: 16709038
[TBL] [Abstract][Full Text] [Related]
60. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]